The USFDA has recently approved tepotinib to treat adult patients with metastatic non-small cell lung cancer and mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Tepotinib blocks phosphorylation of MET and thus inhibits tumor cell proliferation, migration, and anchorage-independent growth. The approval was granted based on clinical trials conducted on treatment-naïve (n = 164) and previously treated (n = 149) patients. Clinical evidence Patients received 450 mg of tepotinib daily until experiencing toxicity or disease progression.
Among the treatment-naïve group, the overall response rate (ORR) was 57% and 40% of patients had duration of response (DOR) 12 months or above. Among the previously treated group, ORR was 45% and 36% of patients had DOR 12 months or above. Dosage and Administration – 450 mg orally once daily with food Side effects Edema, fatigue, nausea,…
